Lamivudine/raltegravir

{{Short description|Combination drug for HIV}}

{{Use dmy dates|date=January 2020}}

{{Infobox drug

| drug_name =

| type = combo

| component1 = Lamivudine

| class1 = Reverse-transcriptase inhibitor

| component2 = Raltegravir

| class2 = Integrase inhibitor

| pronounce =

| tradename = Dutrebis

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US = Rx-only

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Oral

| ATCvet =

| ATC_prefix = J05

| ATC_suffix = AR16

| CAS_number = 2446160-46-7

| PubChem =

| DrugBank =

| KEGG = D10754

}}

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS. It contains lamivudine and raltegravir. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.{{cite web|title=Dutrebis (lamivudine and raltegravir)|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206510lbl.pdf|archive-url=https://web.archive.org/web/20170118193314/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206510lbl.pdf|url-status=dead|archive-date=18 January 2017|website=U.S. Food and Drug Administration (FDA)|accessdate=10 December 2017}}{{cite web | title=Dutrebis (lamivudine and raltegravir) tablet | website=U.S. Food and Drug Administration (FDA) | date=11 April 2016 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206510Orig1s000TOC.cfm | archive-url=https://web.archive.org/web/20160415074845/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206510Orig1s000TOC.cfm | url-status=dead | archive-date=15 April 2016 | access-date=24 January 2020}}

Lamivudine/raltegravir is not available in the United States.{{cite web | title=Dutrebis (lamivudine and raltegravir) FDA Approval History | website=Drugs.com | date=6 February 2015 | url=https://www.drugs.com/history/dutrebis.html | access-date=24 January 2020}}